San Diego-primarily based Viking Therapeutics marked by itself as a serious competitor during the weight loss drug market place in February after revealing promising information from a mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection and in March th